This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoGenomics Announces Upward Revision To Q1 2012 Revenue Guidance

FT. MYERS, Fla., March 5, 2012 /PRNewswire/ -- NeoGenomics, Inc. (NASD OTCQB: NGNM ) announced today that it was revising upward its previously issued revenue guidance for the first quarter of 2012.  The Company now expects revenue of approximately $14.5 - $15.0 million for the first quarter, an increase from the prior guidance of $13.5 - $14.0 million released on February 16, 2012.  At the $14.75 million midpoint of this revised guidance range, first quarter revenue would be 68% higher than it was in the first quarter of last year. 

The Company also reiterated that it expects to be profitable in Quarter 1 with earnings of $0.00 to $0.01 per share, but is suspending its previously issued guidance for the full year 2012 pending a review of the implications of certain provisions in the Middle Class Tax Relief Act of 2012 (the "Act").  The provisions of the Act that affect medical laboratories, pathologists and hospitals were first proposed on Tuesday evening February 14th, and then passed by Congress on February 17th with very little input from hospitals and the laboratory industry.  The Act was then signed into law on February 22, 2012. 

Among other items, the Act reduces reimbursements on the Medicare Clinical Lab Fee Schedule by 2% beginning in 2013, and sets an expiration date of June 30, 2012 for the Technical Component ("TC") Grandfather Clause.  The TC Grandfather Clause has extended a decades-old practice by independent labs and eligible hospitals under which labs bill Medicare directly for reimbursement of the technical component of certain anatomic pathology services.  The clause has been renewed year after year for over a decade, and the Act further extends it until June 30, 2012.  However, if it is not extended again beyond June 30, 2012, labs will be required to bill hospitals directly for such technical component testing, and hospitals will have to absorb the additional costs without any additional reimbursement from Medicare.      

Douglas VanOort, the Company's Chairman and CEO, commented, "We experienced strong and broad-based revenue growth in both January and February, and we expect this excellent growth momentum to continue.  However, we are disappointed that anticipated changes in the TC Grandfather Clause will now require us to concentrate on changing our billing practices rather than on improving cancer genetic testing.  Until we can quantify the implications of these regulatory changes, we are suspending our full-year 2012 guidance.  Over the next few months, we will focus on developing strategies to offset the potential negative impacts from this new legislation in the event that the TC Grandfather Clause is not extended further." 

The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan.  Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,084.49 +33.74 0.20%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,830.47 +19.6820 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs